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Abstract
Background: African trypanosomiasis is a parasitic infection sporadically imported to Europe by tourists or
immigrants returning from endemic areas. We present the first and an unusual case of East African trypanosomiasis
imported to Poland by a patient returning from a tourist trip to Uganda and Rwanda, which was successfully
treated with pentamidine.
Case presentation: A 61-year-old Polish man was admitted to the Department because of high-grade fever and
multi-organ dysfunction after a tourist trip to East Africa. He experienced a single tsetse fly bite during a safari trip
to the Queen Elizabeth National Park in Uganda. On admission, his clinical status was severe, with high fever of
41ºC, preceded by chills, bleeding from the gums and oral mucosa, haemorrhages at the sites of venipuncture,
numerous ecchymoses, fine-spotted skin rash, tachycardia, hepatosplenomegaly, dehydration, jaundice, dyspnoea,
hypoxaemia, generalised oedema and oliguria. There was a typical non-painful trypanosomal chancre with central
necrosis and peripheral erythema on his left arm. Laboratory investigations showed leucopenia, thrombocytopenia,
haemolytic anaemia, hyperbilirubinaemia, hypoglycaemia, elevated creatinine and urea, high activity of aminotransferases,
elevated levels of inflammatory markers, hypoproteinaemia, proteinuria, abnormal clotting and bleeding times, low
fibrinogen level, metabolic acidosis, and electrolyte disturbances. A peripheral blood smear showed numerous
Trypanosoma brucei trypomastigotes with a massive parasitaemia of 100,000/μl. T. brucei rhodesiense subspecies was
finally identified on the basis of the characteristic serum resistance-associated gene using a polymerase chain reaction,
and a seroconversion of specific immunoglobulin M and G antibodies in the peripheral blood by enzyme-linked
immunosorbent assay. Serological tests for T. brucei gambiense subspecies were negative. A severe clinical course of acute
rhodesiense trypanosomiasis with renal failure, respiratory distress, disseminated intravascular coagulation syndrome,
haemolysis, liver insufficiency and myocarditis was confirmed. Intensive anti-parasitic and symptomatic treatment was
immediately instituted, including intravenous pentamidine, plasmaphereses, oxygen therapy, blood transfusion,
catecholamine administration, and fluid infusions, as well as haemostatic, hepatoprotective, anti-inflammatory, antipyretic
and diuretic drugs. The final outcome was a full recovery with no late sequelae.
Conclusion: Sleeping sickness should always be considered in the differential diagnosis of fever in people returning from
safari trips to the national parks or nature reserves of sub-Saharan Africa.
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Background
Human African trypanosomiasis (HAT) is a protozoan,
vector-borne infection occasionally imported to Europe by
tourists, military personnel, expatriates and immigrants
returning from endemic areas of sub-Saharan Africa. Only
a handful of cases are reported every year in European
tropical institutes [1,2]. A delay in medical diagnosis or in-
appropriate treatment of the disease, which is usually
rarely considered in the differential diagnosis of fever in a
patient returning from tropical areas, may lead to severe
multi-organ injury or even a fatal clinical prognosis during
an acute period of generalised parasitaemia of East African
trypanosomiasis or in a chronic phase of meningoenceph-
alitis in the West African form of the infection [3,4]. West
African trypanosomiasis, which circulates in the human
environment, is characterised by a more benign, slowly
progressing and chronic clinical course of the disease. On
the contrary, infection with Trypanosoma brucei rhode-
siense, which is a pure zoonosis transmitted through bites
of infected tsetse flies (Glossina spp.) that feed on cattle or
ungulate wild animals, is characterised by a typical chan-
cre at the bite site, followed by sudden onset, high grade
fever 3 to 10 days thereafter, fulminant manifestatation of
clinical symptoms and a poor prognosis. Usually there is
rapid progression towards multi-organ disease, rendering
appropriate treatment a medical emergency. In many in-
stances, the recommended first line treatment with sura-
min is not readily available, and the lack of promptly
instituted specific therapy may increase the risk of serious
complications.
HAT caused by T. b. gambiense, imported to Europe by
travellers, is more frequently observed in migrants and ex-
patriates residing in rural endemic areas, while more se-
vere T. b. rhodesiense infections are mainly reported in
tourists and hunters returning from East African national
parks and game ranches, where antelopes constitute an
important reservoir of the protozoan.
Uganda is a unique country in the world, where T. b. rho-
desiense (responsible for acute disease) and T. b. gambiense
subspecies (causing the chronic form of the infection), both
occur endemically. More disquietingly, however, areas af-
fected by East African trypanosomiasis have significantly in-
creased and continuously enlarged within the past few
years, to include new districts and foci through repopula-
tion and subsequent migration of the livestock reservoir of
this neglected anthropozoonotic disease. Cattle are the
main reservoir for T. b. rhodesiense in rural areas. By con-
trast, West African trypanosomiasis caused by T. b. gam-
biense has no documented epidemiologically significant
animal reservoir in the natural environment. Suitable Glos-
sina spp. vectors abound in the Queen Elizabeth National
Park, frequently visited by foreign travellers as well, and the
replenishment of wildlife has probably amplified the natural
host reservoir of the parasite. Three species of the vector
are currently responsible for the T. b. rhodesiense infection
of humans in Uganda Glossina fuscipes fuscipes, G. palli-
dipes and G. morsitans morsitans, but only the first two
constitute a source for parasite transmission in the Queen
Elizabeth National Park. At present, West African trypano-
somiasis is confined to the northern part of Uganda where
G. fuscipes fuscipes predominates, but the dividing line be-
tween both species is narrowing [5-8].
In this study, we present the first and an unusual case of
acute East African trypanosomiasis, imported to Poland by
a patient returning from a tourist trip to Uganda and
Rwanda, which was successfully treated with pentamidine.
This is probably the first case of imported severe Rho-
desian trypanosomiasis with extremely high intensity
of infection and sensitivity to pentamidine described in
the literature [1,9].
Case presentation
On 28 July 2009, a 61-year-old Polish man, with no pre-
vious eventful medical history, was transferred as an
emergency from a regional hospital in an air ambulance
and admitted to the Department of Tropical Diseases
because of high-grade fever and multi-organ dysfunction
after a trip to East Africa. The patient spent 18 days on
a package tourist trip to Uganda and Rwanda organised
by a Polish travel agency and had returned 4 days prior
to admission. During the travel, in a group of 16 other
tourists, he visited the most famous national parks in
Uganda and Rwanda, and had close contact with some
wild animals (mainly gorillas and chimpanzees) but never
participated in hunting. He did not comply with tropical
hygiene measures; he frequently wore shorts and a T-shirt.
He experienced a painful single tsetse fly bite on his left
arm on 14 July 2009 during a safari trip to the Queen
Elizabeth National Park in Uganda, but did not seek for
medical advice from the local physician. No other person
from the Polish tourist group was infected.
Before the trip to the tropics, the patient did not con-
sult with any travel medicine specialist; however, he
took antimalarial chemoprophylaxis in form of atova-
quone and proguanil (Malarone) regularly, and was vac-
cinated against selected infectious diseases in a regional
sanitary-epidemiological centre (yellow fever, tetanus,
viral hepatitis A and B). For 10 years he had been travel-
ling to various tropical and subtropical countries, includ-
ing those of Africa, Latin America, Southeast Asia and the
Far East islands of Indonesia. He had experienced multiple
insect bites in the tropics, but had never visited a specialist
in travel medicine or tropical diseases.
Six days after a whole day spent at the Queen Elizabeth
National Park in Uganda, a painless skin lesion appeared
on the left arm, at the site of the tsetse fly bite. Two days
later, he had a high fever of 40°C proceeded by chills, to-
gether with weakness, fatigue and malaise. After arrival in
Paul et al. BMC Infectious Diseases 2014, 14:111 Page 2 of 8
http://www.biomedcentral.com/1471-2334/14/111
Poland on 24 July 2009, he went directly to his family doc-
tor and was treated with a beta-lactam antibiotic for 4 days
without any improvement. On the 7th day of illnesses,
after symptoms of multi-organ injury had begun, he was
admitted to a regional infectious diseases hospital in
South-East Poland, and then transferred to the Depart-
ment of Tropical and Parasitic Diseases in Poznań with
the suspicion of complicated malaria, viral haemorrhagic
fever or bacterial sepsis.
On admission, on the 8th day of clinical symptoms, the
clinical status of the patient was severe, with a fever of
41°C, chills, numerous ecchymoses on the lower extrem-
ities, petechiae on a large area of the skin of the abdomen
and chest, fine-spotted non-pruritic skin rash, tachycardia
of 124/min, hepatosplenomegaly, signs of dehydration,
prostration, jaundice, dyspnoea, hypoxaemia (oxygen sat-
uration 78.9%), generalised oedema and oliguria (urine
output 250 ml). Most worrying were signs of bleeding
from the gums and oral mucosa and haemorrhages at the
sites of venipuncture, suggestive of disseminated intravas-
cular coagulation (DIC) syndrome (Figures 1 and 2A). The
patient was conscious and very well orientated (15 points
in Glasgow Coma Scale) but seemed to respond rather
slowly to commands. On his left arm, there was still a vis-
ible, typical, painless trypanosomal chancre of 6 cm in
diameter with a depressed dark centre surrounded by per-
ipheral erythema (Figure 2B).
Routine laboratory examinations showed leucopenia
(2.09 G/l), severe thrombocytopenia (10 G/l), shift to the
left in Schilling’s blood count (band cells 25%, segmented
cells 48%), lymphopenia (12%), hyperbilirubinaemia
(2.37 mg/dl), hypoglycaemia (30 mg/dl), elevated concen-
trations of creatinine (2.92 mg/dl) and urea (93 mg/dl),
high activity of the liver enzymes (alanine aminotransfer-
ase 208 U/l, aspartate aminotransferase 217 U/l, gamma-
glutamyl transpeptidase 162 U/l), marked elevation of the
inflammatory markers (C-reactive protein 221 mg/l, pro-
calcitonin 3.22 ng/ml), hypoproteinaemia (6.1 g/dl), pro-
teinuria, presence of hyaline casts in the urine, abnormal
clotting and bleeding times (international normalisation
ratio 1.34, activated partial thromboplastin time 55 s, pro-
thrombin time 16.2 s), low level of fibrinogen (173 mg/dl)
and other parameters consistent with DIC syndrome (D-
dimers > 35.85 mg/l, antithrombin III [ATIII] 61%),
metabolic acidosis (lactic acid 6.5 mmol/l, sO2 65.8%,
pH 7.286, pO2 38.8 mm Hg, pCO2 41.9 mm Hg, HCO3
19.3 mmol/l, BE - 6.7 mmol/l), and electrolyte distur-
bances (Na 137 mmol/l, K 3.09 mmol/l) (Table 1).
On admission, the peripheral blood smear showed
numerous Trypanosoma brucei trypomastigotes, with a
massive parasitaemia of 100,000 per 1 μl using the Car-
pentier’s cell or an average of 45 protozoans in a higher
magnification microscopic field of 1000×, and 116 par-
asites in a lower magnification of 400× in direct mi-
croscopy (Figure 3).
Electrocardiography showed negative T wave in aVR
and precordial leads V2-V6 with sinus tachycardia and
Figure 1 Numerous ecchymoses on the skin of the lower
extremities in a patient infected with T. b. rhodesiense.
Figure 2 Typical clinical manifestations of acute African
trypanosomiasis imported from Uganda: A) Fine-spotted pink rash
on the skin of the abdomen (”trypanid rash”); B) Trypanosomal
chancre on the skin of the left arm.
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pathological left-axis deviation. There was no sign of
bleeding to the central nervous system as was demon-
strated in a computerised tomography scan, or to the
retina on ophthalmoscopic examination. Lumbar punc-
ture showed no trypomastigotes in the precipitate of the
cerebrospinal fluid after centrifugation; leucocyte count
(3 cells/μl) and protein concentration (266 mg/l) were
normal.
Because of the severe clinical condition of the patient,
and the non-availability of suramin on the day of admis-
sion, intensive anti-parasitic treatment with intravenous
pentamidine isethionate (Pentacarinat, Sanofi-Aventis,
Frankfurt am Main, Germany) at a dose of 300 mg every
2 days for 14 days (7 doses) was immediately instituted. At
the same time, symptomatic treatment was commenced,
which included passive oxygen therapy, repeated transfu-
sions of blood (2 units), plasma (9 units), platelets (50
units), antithrombin III (500 units) and 20% albumins
(400 ml), fluid infusions, as well as the administration of
haemostatic, hepatoprotective, anti-inflammatory, antipyr-
etic and diuretic drugs. Because of respiratory distress, the
patient was monitored in an intensive care unit for 6 days.
Treatment was well tolerated and led to a rapid parasite
clearance within 72 hours, after the 2nd dose of pentami-
dine. Renal impairment and electrolyte imbalance did not
require haemodialysis, but we opted for four cycles of
plasmapheresis, starting on the day of the extinction of all
trypomastigotes from the peripheral blood. The complete
destruction of the circulating trypanosomes and the
massive release of antigens caused a single incidence of
hypotension (blood pressure 90/55 mm Hg) and the pa-
tient required an additional dose of catecholamines (nor-
epinephrine). In spite of the transfusions, the platelet
count was lowest on the 2nd day (3 G/l), and other labora-
tory parameters of DIC syndrome were most evident on
the 4th day of hospitalisation (fibrinogen 108 mg/dl, ATIII
55%). Haemolytic anaemia was noticed on the 3rd day of
treatment and was most severe on the 10th day after
Table 1 Clinical and paraclinical features during hospitalisation and follow-up of a patient with African trypanosomiasis
D0 D3 D7 D15 D30 D60 D90 D 120
28-7 31-7 3-8 13-8 2-9 30-9 28-10 8-12
Inoculation chancre + + + + +/− - - -
Fever + + - - - - - -
Anaemia - + + + + - - -
Jaundice + + + - - - - -
Splenomegaly + + + - - - - -
Spontaneous bleeding + + - - - - - -
Respiratory distress + + - - - - - -
Renal injury + + - - - - - -
Hgb (g/dl) 14.5 13.8 10.0 9.2 10.6 15.1 16.4 16.2
Thrombocytes (n/μl) 10000 9000 70000 445000 370000 216000 206000 216000
Parasitaemia (n/μl) 100000 0 0 0 0 0 0 0
ALT (IU/l) 208 362 68 18 20 30 34 29
AST (IU/l) 217 237 48 12 12 20 21 20
Bilirubin (total, mg/dl) 2.37 3.48 4.52 0.76 0.60 0.55 0.68 0.75
Fibrinogen (mg/dl) 173 125 136 256 276 281 274 278
Creatinine (mg/dl) 2.92 1.71 0.57 0.46 0.70 0.91 0.96 0.96
Tbgam IFAT - - - - - - -
Tbgam CATT - - - - - - -
Tbrhod ETat 1:1 - + + + - - -
Tbrhod ETat 1:18 - - - - - - -
Total serum IgM (mg/l) 1610 3530 7030 5050 3370 3120 2170
T.brucei complex PCR-RFLP +
T.b.rhod. PCR SLG polymorphism +
T.b.rhod PCR SRA + (287 bp)
Abbreviations: Hgb hemoglobin, ALT alanine aminotransferase, AST aspartate aminotransferase, Tbgam Trypanosoma brucei gambiense, Tbrhod Trypanosoma brucei
rhodesiense, CATT Card Agglutination Test for Trypanosomiasis, IFAT Indirect Fluorescent Antibody Test, ETat Edinburgh Trypanosoma Antigenic Type, PCR
Polymerase Chain Reaction, RFLP Restriction Fragment Length Polymorphism, SLG Spliced Leader Gene Polymorphism Marker, SRA Serum Resistance-Associated
Gene, “-“ negative result, “+” positive result, bp: base pair.
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admission (Hgb 7.8 g/dl, RBC 2.51 T/l, Hct 23.2%) with an
increase in bilirubin level of up to 5.75 mg/dl. The fever
subsided on the 4th day of anti-trypanosomal therapy.
Normal renal function was restored on the 6th day, signs of
respiratory distress receded on the 7th day, coagulopathy
ceased on the 8th day, and liver enzymes were normalised
on the 10th day of hospitalisation. The electrocardiographic
changes seen on admission normalised during treatment.
The final outcome of the intensive therapy was that of
success, and the patient was discharged home after
3 weeks, without any residual signs of organ dysfunction.
The patient has been asymptomatic since then, and there
have been no signs of disease persistence or reactivation
during the 3 years of clinical and laboratory follow-up.
Diagnostic differentiation of Trypanosoma brucei complex
Molecular diagnosis of East African trypanosomiasis was
done retrospectively after anti-parasitic therapy, using a
two-step test on the pre-treatment whole blood sample
containing trypanosomes (Institute of Tropical Medicine,
Antwerp, Belgium). In the first step, the presence of Try-
panosoma brucei complex was confirmed by means of a
polymerase chain reaction - restriction fragment length
polymorphism (PCR-RFLP) using the small subunit rDNA
marker [10]. In the subsequent step, a specific in-house
PCR-based test to identify T. b. rhodesiense using the
spliced leader gene polymorphism marker was carried out
and proved to produce a positive response. In addition, a
PCR based test for the serum resistance-associated (SRA)
gene specific for T. b. rhodesiense showed a positive result.
Antibody tests for Trypanosoma brucei gambiense and
rhodesiense were carried out using card agglutination test
for trypanosomiasis (CATT), indirect fluorescent antibody
test (IFAT), and enzyme-linked immunosorbent assay
(ELISA) in two different dilutions. The serological tests,
which are produced under full quality control, are cur-
rently manufactured only at the Institute of Tropical
Medicine in Antwerp (Belgium) from where field kits con-
taining reagents, control sera, and test accessories can be
obtained (http://www.itg.be/itg/GeneralSite/default.aspx?
WPID=471&MIID=433&L=E; contact Philippe Büscher;
pbuscher@itg.be). A positive reaction for T. b. rhodesiense
subspecies was observed in the serum samples (Table 1).
Discussion
We presented the first case of sleeping sickness imported
to Poland, and the first case of documented Trypanosoma
brucei infection in a tourist from Central-Eastern Europe.
Moreover, this was the first recorded case in the past
25 years of acute-stage East African trypanosomiasis occur-
ring in a European traveller infected in Uganda (Eastern
Africa).
Although East African trypanosomiasis is hyperen-
demic in the south-eastern part of Uganda, it has spread
to the western and central parts of the country during
the last decade, and this is partially due to the movement
of cattle and their local trading to these regions from the
original infection belt. In fact, HAT has become a re-
emerging parasitic infection of public health concern in
Uganda, where the geographical distribution of tsetse fly-
affected areas has extended to previously uninfected prov-
inces [5-8,11]. According to the National Sleeping Sickness
Control Program in Uganda, more than 2,500 presumed
T. b. rhodesiense cases have been reported since 2000, and
mortality rates are higher in recently affected districts. The
disease has a tendency to a seasonal transmission with the
highest risk from January to March, as spreading of infec-
tion is mostly related to livestock migration and cattle trad-
ing [12].
Among all HAT cases imported to Europe since 2005,
most of them were expatriates or immigrants returning
from sub-Saharan Africa; but during the last years an in-
creasing number of sleeping sickness has been reported in
tourists [1,13-16]. Over the last decade, non-endemic hu-
man infections with T. brucei in European travellers have
been reported mainly from Tanzania, Gabon, Zambia,
Angola, Guinea, Malawi and Central African Republic. So
far, imported HAT cases have been registered in France,
Figure 3 Trypomastigotes of T. b. rhodesiense in the peripheral
blood stained with Giemsa: A) Thick blood film. Magn. 400×;
B) Thin blood film. Magn. 1000x.
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Italy, Spain, the United Kingdom, Belgium, Germany, the
Netherlands, Switzerland and Scandinavia [1,2,17-24].
The presented patient did not comply with any trop-
ical hygiene measures, and wore inappropriate clothing
in areas at risk. European tourists travelling to destina-
tions with a significant risk of HAT, such as national
parks, nature reserves and safari camps, should be
instructed on preventive measures against tsetse bites,
particularly wearing long sleeve shirts and trousers made
of a thick cotton material, without bright or contrasting
colours, impregnated with permethrin, as well as regular
application of insect repellents. If skin symptoms occur,
consultation with an experienced travel medicine clin-
ician should be considered as a matter of urgency, in
order to reduce the high fatality rate if generalised signs
of HAT develop. As in the case of our patient, an inocu-
lation chancre is typically present in nearly all reported
patients with imported HAT [1,18,20,22-24], and it is a
clinical sign of utmost importance in guiding the differ-
ential diagnosis [25]. It may be mistaken for a rickettsial
chancre by less experienced health practitioners or simply
overlooked with potentially disastrous consequences [4].
According to Odiit and colleagues, most HAT cases that
originated from epidemic areas in Uganda were not diag-
nosed by the national health care system, including fatal
cases, despite their contact with medical facilities [26].
Early diagnosis and prompt administration of effective
anti-parasitic treatment are the key prognostic factors in
a patient’s clinical prognosis and increase the probability
of survival. In HAT caused by T. b. rhodesiense, the dis-
ease has a tendency of rapid progression to the stage of
central nervous system involvement between 3 weeks to
2 months after a primary infection. Most HAT deaths
are reported within the first 6 months of clinical mani-
festations [27-29].
The role of the geographical location, parasite geno-
type and specific host inflammatory cytokine response
in the clinical expression of the disease in humans has
been studied by many authors. Currently, an analysis
of some genetic markers of T. b. rhodesiense virulence
seems to be the best option for a predictive evaluation
of HAT cases, and a practical determination of clinical
course severity. MacLean et al. reported that infections
with the Tororo genotype were characterised by an in-
creased probability of disease progression and a rapid de-
velopment of the meningoencephalitic stage, and higher
plasma interferon gamma levels, while the Soroti genotype
was well correlated with a milder clinical course of HAT
cases [28]. Similarly, severe clinical status of HAT patients
and its rapid progression to meningoencephalitis in T. b.
rhodesiense infections from Uganda was related to ele-
vated concentrations of tumour necrosis factor alpha
(TNF-alpha) in serum samples. On the contrary, more be-
nign infections with T. b. rhodesiense in Malawi were
associated with high levels of transforming growth factor
beta but not TNF-alpha activation [29].
In the reported case, circulating trypomastigotes were
easily identified in the peripheral blood samples collected
on admission at the emergency room, and stained by
Giemsa. The short incubation period of the infection and
the severe clinical status of the patient, accompanied by
multi-organ injury, suggested an acute Rhodesian form of
HATcaused by a highly pathogenic strain. Molecular differ-
entiation of T. brucei complex by finding the characteristic
SRA gene and S-locus glycoprotein gene polymorphism
marker of T. b. rhodesiense subspecies, in whole blood
collected before treatment, using a PCR technique,
considerably improved the diagnostic accuracy and fi-
nally confirmed the clinical diagnosis (Table 1).
The SRA gene, first isolated from a Ugandan strain of T.
b. rhodesiense, has been shown to be a marker of the para-
site invasiveness for humans. This gene has also been
identified in several other isolates of T. b. rhodesiense from
Ethiopia, Kenya, Tanzania, Zambia and Botswana, but not
in the other human pathogenic trypanosomes in Africa,
including T. b. gambiense [13,30]. Further analysis showed
a significant SRA gene polymorphism and differences in
immune response profiles in host populations from vari-
able geographical areas [29]. Strain typing using microsat-
ellite markers has proven the molecular heterogeneity
between different T. b. rhodesiense isolates, which can be
related to considerable differences in the degree of infect-
ivity to human beings according to genetic variants [28].
Serological diagnosis, particularly the CATT widely used
in the field by medical officers, is more helpful in T. b.
gambiense infections, when trypomastigotes may be diffi-
cult to be found in the peripheral blood or lymph. Home-
made IFAT or ELISA performed in scientific laboratories
is very useful for the differential diagnosis between both
subspecies. In the case described above, we detected a
seroconversion of immunoglobulin (Ig) M and IgG spe-
cific antibodies in the peripheral blood by ELISA on the
7th day of hospitalisation or 15th day of clinical symptoms.
Total IgM reached the highest level on the 7th day of
treatment and persisted longer than Trypanosoma-specific
immunoglobulins. Serological tests for T. b. gambiense sub-
species (CATT, IFAT, ELISA) were all negative, confirming
the final diagnosis (Table 1).
Pentamidine is recommended to be the standard therapy
for acute West African trypanosomiasis. Suramin is gener-
ally considered as the drug of choice for an early stage of
Rhodesian sleeping sickness; melarsoprol alone or in a
combination with nifurtimox is proposed for a late stage of
the illness [3,13,31,32]. A combined therapy with suramin
and eflornithine seems to be very promising [32,33]. In case
of unavailability of suramin, treatment with pentamidine
plays a crucial role in the prevention of severe complica-
tions of second-stage HAT, characterised by poor clinical
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prognosis [1]. In a large study of 56 travellers from non-
endemic countries infected with T. b. rhodesiense, 7% were
treated with pentamidine alone [34]. In some other pa-
tients with early stage of Rhodesian sleeping sickness,
anti-protozoan therapy with pentamidine has been initi-
ated and then switched to suramin upon availability [15].
Therefore, pentamidine is accepted to be an alternative
drug for the management of an early phase of T. b. rhode-
siense infection [35].
Among all imported cases of East African trypanosomia-
sis reported in the literature, this was also the first docu-
mented patient successfully treated with pentamidine
instead of suramin, despite the critically high parasitaemia,
which is extremely rarely observed. After the administra-
tion of suramin, the blood stage trypomastigotes disap-
peared within 3 days in all recently imported cases [13,16].
This was finally observed in this patient treated with pent-
amidine alone. Following the elimination of parasitaemia,
clinical recovery occurred fairly rapidly. Clinical symptoms
and laboratory parameters of multi-organ injury resolved
within 10 days, without late complications. There have
been no signs of disease persistence or relapse during the
3 years of clinical follow-up.
Patients should usually be followed-up for 3 months
(acute haematogenous stage) or for up to 2 years (menin-
goencephalitic stage), to confirm complete eradication.
There is a risk of the chronic suppression of the disease in
improperly treated patients [32]. In this case, anti - T. b.
rhodesiense IgM-IgG antibodies were observed in serum
samples for 4 weeks and were later not detectable. Total
IgM lasted longer, but after significantly rising 1 week after
admission to hospital, it tended to diminish during the
follow-up period (Table 1). During serological monitoring,
serum IgM levels may actually increase before they finally
decrease, and should not be regarded as a sign of treat-
ment failure. Serum antibodies may appear well after the
commencement of treatment, and diminish over time with
the elimination of parasites. A 2-fold reduction in serum
antibody titre may be interpreted as a sign of at least tem-
porary parasite reduction, but it cannot be used to ascer-
tain definitive cure [36]. Further analysis of some genetic
markers of sensitivity and/or resistance to pentamidine in
T. b. rhodesiense strains from Uganda has been promising.
Conclusions
We recommend that proper health education on threats
related to contact with tsetse flies and the possibilities of
their prevention is important for persons travelling to
areas with a high risk of T. brucei infection in Africa.
Sleeping sickness should always be considered in the dif-
ferential diagnosis of fever in people returning from safari
trips to national parks or nature reserves of sub-Saharan
Africa. Imported African trypanosomiasis should be
treated in reference centres of tropical diseases or travel
medicine, which have good clinical experience in rare
exotic infections and direct access to intensive care facil-
ities. Finally, in T. b. rhodesiense infections without central
nervous system involvement, treatment with pentamidine
may be considered an option until access to suramin has
been achieved.
Consent
Written informed consent was obtained from the patient
for the publication of this case report and any accom-
panying images. A copy of the written consent is avail-
able for review by the Editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MP was directly responsible for the patient, performed the clinical and
parasitological examinations and was a major contributor in writing the case
report. PS coordinated intensive care monitoring. ME carried out the
molecular biology tests. DG was responsible for the immunoassays. JC
conceived the study, and participated in its design and coordination and
helped to draft the manuscript. JS reviewed the paper. All the authors read
and approved the final version of the manuscript.
Acknowledgements
The authors wish to thank Krystyna Frąckowiak from the Laboratory of
Parasitology, the University Hospital in Poznań (Poland) for her technical
assistance. Professor Leon Drobnik, a Head of the Department of
Anaesthesiology, Intensive Therapy and Pain Treatment, the University of
Medical Sciences in Poznań was responsible for managing intensive medical
care of the patient. We are grateful to Dr. Clinton Muoto from the
Department and Clinic of Tropical and Parasitic Diseases, the University of
Medical Sciences in Poznań for checking the language.
Author details
1Department and Clinic of Tropical and Parasitic Diseases, University of
Medical Sciences, Przybyszewskiego 49, Poznań, Poland. 2Department of
Anaesthesiology, Intensive Therapy and Pain Treatment, University of Medical
Sciences, Poznań, Poland. 3Department of Clinical Sciences, Institute of
Tropical Medicine, Antwerp, Belgium. 4Department of Veterinary Sciences,
Institute of Tropical Medicine, Antwerp, Belgium.
Received: 21 August 2013 Accepted: 14 February 2014
Published: 27 February 2014
References
1. Gautret P, Clerinx J, Caumes E, Simon F, Jensenius M, Loutan L,
Schlagenhauf P, Castelli F, Freedman D, Miller A, Bronner U, Parola P:
Imported human African trypanosomiasis in Europe, 2005–2009.
Euro Surveill 2009, 14. Available online: http://www.eurosurveillance.org/
ViewArticle.aspx?Articleid=19327.
2. Migchelsen SJ, Büscher P, Hoepelman AI, Schallig HD, Adams ER: Human
African trypanosomiasis: a review of non-endemic cases in the past
20 years. Int J Infect Dis 2011, 15:e517–e524.
3. Braakman HM, van de Molengraft FJ, Hubert WW, Boerman DH: Lethal
African trypanosomiasis in a traveler: MRI and neuropathology.
Neurology 2006, 66:1094–1096.
4. Klaassen B, Smit YG: A fatal outcome of acute East African sleeping
sickness in Tanzania [in Dutch]. Tijdschr Infect 2009, 4:61–65.
5. Berrang-Ford L, Berke O, Abdelrahman L, Waltner-Toews D, McDermott J:
Spatial analysis of sleeping sickness, southeastern Uganda, 1970–2003.
Emerg Infect Dis 2006, 12:813–820.
6. Picozzi K, Fèvre EM, Odiit M, Carrington M, Eisler MC, Maudlin I, Welburn SC:
Sleeping sickness in Uganda: a thin line between two fatal diseases.
BMJ 2005, 331:1238–1241.
Paul et al. BMC Infectious Diseases 2014, 14:111 Page 7 of 8
http://www.biomedcentral.com/1471-2334/14/111
7. Hutchinson OC, Fèvre EM, Carrington M, Welburn SC: Lessons learned from
the emergence of a new Trypanosoma brucei rhodesiense sleeping
sickness focus in Uganda. Lancet Infect Dis 2003, 3:42–45.
8. Berrang-Ford L, Odiit M, Maiso F, Waltner-Toews D, McDermott J: Sleeping
sickness in Uganda: revisiting current and historical distributions. Afr
Health Sci 2006, 6:223–231.
9. Paul M: Trypanosomiasis – Poland ex Uganda (Queen Elizabeth National Park).
ProMED-mail post. 20090810.2844. 10 Aug 2009. Available from: http://
www.promedmail.org/direct.php?id=264400.
10. Geysen D, Delespaux V, Geerts S: PCR-RFLP using Ssu rDNA amplification
as an easy method for species specific diagnosis of Trypanosoma species
in cattle. Vet Parasitol 2003, 110:171–180.
11. Fèvre EM, Picozzi K, Fyfe J, Waiswa C, Odiit M, Coleman PG, Welburn SC: A
burgeoning epidemic of sleeping sickness in Uganda. Lancet 2005,
366:745–747.
12. Berrang-Ford L, Wamboga C, Kakembo ASL: Trypanosoma brucei
rhodesience sleeping sickness, Uganda. Emerg Infect Dis 2012,
18:1686–1687.
13. Clerinx J, Vlieghe E, Asselman V, Van de Casteele S, Maes MB, Lejon V:
Human African trypanosomiasis in a Belgian traveler returning from the
Masai Mara area, Kenya, February 2012. Euro Surveill 2012, 17. Available
on-line: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20111.
14. Cottle LE, Peters JR, Hall A, Bailey JW, Noyes HA, Remington JE, Beeching J,
Squire SB, Beadsworth MBJ: Multiorgan dysfunction caused by travel-
associated African trypanosomiasis. Emerg Infect Dis 2012, 18:287–289.
15. Gobbi F, Bisoffi Z: Human African trypanosomiasis in travelers to Kenya.
Euro Surveill 2012, 17. Available on-line: http://www.eurosurveillance.org/
ViewArticle.aspx?ArticleId=20109.
16. Wolf T, Wichelhaus T, Göttig S, Kleine C, Brodt HR, Just-Nuebling G: Trypano-
soma brucei rhodesiense infection in a German traveller returning from
the Masai Mara area, Kenya, January 2012. Euro Surveill 2012, 17. Available
on-line: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20114.
17. Mendonca Melo M, Rasica M, van Thiel PP, Richter C, Kager PA, Wismans PJ:
Three patients with African sleeping sickness following a visit to
Tanzania [in Dutch]. Ned Tijdschr Geneeskd 2002, 146:2552–2556.
18. Moore DAJ, Edwards M, Escombe R, Agranoff D, Bailey JW, Squire B,
Chiodini PL: African trypanosomiasis in travelers returning to the United
Kingdom. Emerg Infect Dis 2002, 8:74–76.
19. Ezzedine K, Darie H, Le Bras M, Malvy D: Skin features accompanying
imported human African trypanosomiasis: hemolymphatic Trypanosoma
gambiense infection among two French expatriates with dermatologic
manifestations. J Travel Med 2007, 14:1992–1996.
20. Jelinek T, Bisoffi Z, Bonazzi L, van Thiel P, Bronner U, de Frey A, Gundersen
SG, McWhinney P, Ripamonti D: Cluster of African trypanosomiasis in
travelers to Tanzanian national parks. Emerg Infect Dis 2002, 8:634–635.
21. Hope-Rapp E, Moussa Coulibaly O, Klement E, Danis M, Bricaire F, Caumes E:
Double trypanosomal chancre revealing West African trypanosomiasis in
a Frenchman living in Gabon [in French]. Ann Dermatol Venereol 2009,
136:341–345.
22. Croft AM, Kitson MM, Jackson CJ, Minton EJ, Friend HM: African
trypanosomiasis in a British soldier. Mil Med 2007, 172:765–769.
23. Nadjm B, Tulleken CV, MacDonald D, Chiodini P: East African trypanosomiasis
in a pregnant traveller. Emerg Infect Dis 2009, 15:1866–1867.
24. Malvy D, Djossou F, Weill FX, Chapuis P, Longy-Boursier M, Le Bras M:
Human African trypanosomiasis from Trypanosoma brucei gambiense
with inoculation chancre in a French expatriate [in French]. Med Trop
(Mars) 2001, 6:323–327.
25. Urech K, Neumayr A, Blum J: Sleeping sickness in travelers – do they
really sleep? PLoS Negl Trop Dis 2011, 5:e1358. doi:10.1371/journal.
pntd.0001358.
26. Odiit M, Coleman PG, Liu WC, McDermott JJ, Fèvre EM, Welburn SC,
Woolhouse ME: Quantifying the level of under-detection of Trypanosoma
brucei rhodesiense sleeping sickness cases. Trop Med Int Health 2005,
10:840–849.
27. Odiit M, Kansiime F, Enyaru JC: Duration of symptoms and case fatality of
sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo,
Uganda. East Afr Med J 1997, 74:792–795.
28. MacLean L, Odiit M, MacLeod A, Morrison L, Sweeney L, Cooper A, Kennedy PG,
Sternberg JM: Spatially and genetically distinct African Trypanosome virulence
variants defined by host interferon-gamma response. J Infect Dis 2007,
196:1620–1628.
29. MacLean L, Chisi JE, Odiit M, Gibson WC, Ferris V, Picozzi K, Sternberg JM:
Severity of human African trypanosomiasis in East Africa is associated
with geographic location, parasite genotype, and host inflammatory
cytokine response profile. Infect Immun 2004, 72:7040–7044.
30. Gibson W, Backhouse T, Griffiths A: The human serum resistance
associated gene is ubiquitous and conserved in Trypanosoma brucei
rhodesiense throughout East Africa. Infect Genet Evol 2002, 1:207–214.
31. Pépin J, Milord F: The treatment of human African trypanosomiasis.
Adv Parasitol 1994, 33:1–47.
32. Clerinx J, Taelman H, Bogaerts J, Vervoort T: Treatment of late stage
rhodesiense trypanosomiasis using suramin and eflornithine: report of
six cases. Trans R Soc Trop Med Hyg 1998, 92:449–450.
33. Bacchi CJ, Nathan HC, Yarlett N, Goldberg B, McCann PP, Sjoerdsma A, Saric M,
Clarkson AB Jr: Combination chemotherapy of drug-resistant Trypanosoma
brucei rhodesiense infections in mice using DL-alpha-
difluoromethylornithine and standard trypanocides. Antimicrob Agents
Chemother 1994, 38:563–569.
34. Simarro PP, Franco JR, Cecchi G, Paone M, Diarra A, Ruiz Postigo JA, Jannin JG:
Human African trypanosomiasis in non-endemic countries (2000–2010).
J Travel Med 2012, 19:44–53.
35. Ripamonti D, Massari M, Arici C, Gabbi E, Farina C, Brini M, Capatti C, Suter F:
African sleeping sickness in tourists returning from Tanzania: the first 2
Italian cases from a small outbreak among European travelers. J Infect Dis
2002, 34:e18–e22.
36. Lejon V, Ngoya DM, Boelaert M, Büscher P: A CATT negative result after
treatment for human African trypanosomiasis is no indication for cure.
PLoS Negl Trop Dis 2010, 4:e590. doi:10.1371/journal.pntd.0000590.
doi:10.1186/1471-2334-14-111
Cite this article as: Paul et al.: Outcome of acute East African
trypanosomiasis in a Polish traveller treated with pentamidine. BMC
Infectious Diseases 2014 14:111.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Paul et al. BMC Infectious Diseases 2014, 14:111 Page 8 of 8
http://www.biomedcentral.com/1471-2334/14/111
